174 related articles for article (PubMed ID: 7086194)
1. Pathogenesis of scleroderma (systemic sclerosis).
LeRoy EC
J Invest Dermatol; 1982 Jul; 79 Suppl 1():87s-89s. PubMed ID: 7086194
[TBL] [Abstract][Full Text] [Related]
2. [Vascular lesions and fibroblast metabolism in inflammatory diseases].
Lapière CM
Phlebologie; 1987; 40(1):21-9. PubMed ID: 3575433
[TBL] [Abstract][Full Text] [Related]
3. The connective tissue in scleroderma.
LeRoy EC
Coll Relat Res; 1981 Apr; 1(3):301-8. PubMed ID: 6286231
[No Abstract] [Full Text] [Related]
4. On scleroderma. Mast cells, endothelial cells, and fibroblasts.
Claman HN
JAMA; 1989 Sep; 262(9):1206-9. PubMed ID: 2668581
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of progressive systemic sclerosis.
Haustein UF; Herrmann K; Böhme HJ
Int J Dermatol; 1986 Jun; 25(5):286-93. PubMed ID: 3522447
[No Abstract] [Full Text] [Related]
6. Activation of dermal connective tissue in scleroderma.
Kähäri VM
Ann Med; 1993 Dec; 25(6):511-8. PubMed ID: 8292298
[TBL] [Abstract][Full Text] [Related]
7. The pathogenesis of systemic sclerosis.
LeRoy EC
Clin Exp Rheumatol; 1989; 7 Suppl 3():S135-7. PubMed ID: 2691149
[TBL] [Abstract][Full Text] [Related]
8. Deciphering the pro-fibrotic phenotype of fibroblasts in systemic sclerosis.
Maier C; Distler JH; Beyer C
Exp Dermatol; 2014 Feb; 23(2):99-100. PubMed ID: 24476007
[TBL] [Abstract][Full Text] [Related]
9. Replication and phenotypic expression of control and scleroderma human fibroblasts: responses to growth factors.
LeRoy EC; Mercurio S; Sherer GK
Proc Natl Acad Sci U S A; 1982 Feb; 79(4):1286-90. PubMed ID: 6461858
[TBL] [Abstract][Full Text] [Related]
10. [Pathogenesis of skin scleroderma--literature review].
Wojas-Pelc A; Lipko-Godlewska S
Przegl Lek; 2005; 62(5):310-3. PubMed ID: 16334538
[TBL] [Abstract][Full Text] [Related]
11. Endothelin and collagen vascular disease: a review with special reference to Raynaud's phenomenon and systemic sclerosis.
Yamane K
Intern Med; 1994 Oct; 33(10):579-82. PubMed ID: 7827371
[TBL] [Abstract][Full Text] [Related]
12. Scleroderma fibroblast phenotype is modulated by endothelial cell co-culture.
Denton CP; Xu S; Welsh KI; Pearson JD; Black CM
J Rheumatol; 1996 Apr; 23(4):633-8. PubMed ID: 8730117
[TBL] [Abstract][Full Text] [Related]
13. Scleroderma: pathogenic factors and current management.
Penny R
Aust N Z J Med; 1978; 8 Suppl 1():143-8. PubMed ID: 365159
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of scleroderma: the interrelationship of the immune and vascular hypotheses.
Sternberg EM
Surv Immunol Res; 1985; 4(1):69-80. PubMed ID: 3890057
[No Abstract] [Full Text] [Related]
15. Is Nox4 a key regulator of the activated state of fibroblasts in systemic sclerosis?
Böhm M; Dosoki H; Kerkhoff C
Exp Dermatol; 2014 Sep; 23(9):679-81. PubMed ID: 25040787
[TBL] [Abstract][Full Text] [Related]
16. The vascular defect in scleroderma (systemic sclerosis).
Leroy EC
Acta Med Scand Suppl; 1987; 715():165-7. PubMed ID: 3495959
[No Abstract] [Full Text] [Related]
17. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis.
Pattanaik D; Postlethwaite AE
Discov Med; 2010 Aug; 10(51):161-7. PubMed ID: 20807477
[TBL] [Abstract][Full Text] [Related]
18. Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGF.
Denton CP; Xu S; Black CM; Pearson JD
J Invest Dermatol; 1997 Mar; 108(3):269-74. PubMed ID: 9036923
[TBL] [Abstract][Full Text] [Related]
19. [Systemic sclerosis and scleroderma circumscripta--disturbances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin].
Dziankowska-Bartkowiak B; Zebrowska A; Wagrowska-Danielewicz M; Kobos J; Waszczykowska E
Przegl Lek; 2009; 66(12):1040-5. PubMed ID: 20514902
[TBL] [Abstract][Full Text] [Related]
20. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?
Yamamoto T
Arch Dermatol Res; 2006 Feb; 297(8):333-44. PubMed ID: 16402183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
